Our Research Impact
For more than 40 years, Cancer Research and Treatment Fund (CR&T) has been a driving force in funding original and translational cancer research (bringing laboratory results to the patients and patient issues to the research lab). Founded by Dr. Richard T. Silver, CR&T utilizes a rapid and agile funding model for research that advances the treatment of blood malignancies as well as common solid tissue cancers.
Historically, research funded by CR&T has emphasized the belief that advances in the treatment of blood cancers lead to clues for understanding and curing other types of cancers. As a result, our research focuses on blood cancers, including myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma, as well as other common cancers such as breast and lung cancer.
Through the 1970s, CR&T funded research centered on treatments for lymphoma, non-Hodgkin’s lymphoma, Hodgkin’s disease, leukemia and multiple myeloma. In the 1980s and 1990s, our focus shifted to include leukemia, with an emphasis on chronic myeloid leukemia, one of the four myeloproliferative neoplasms (MPNs). In the 2000s, CR&T has funded research focusing on the remaining three MPNs: polycythemia vera (PV), essential thrombocytosis (ET) and myelofibrosis (MF)
Over the past 15 years, CR&T has provided more than $12 million in research grants, including sizeable contributions to the Weill Cornell Medical College for blood cancer research and “seed funding” for physician-scientists working to advance the treatment for a range of cancers.
Some of the major accomplishments of the physician-scientists CR&T has helped fund include:
- Participated in breakthrough discoveries in the treatment of chronic myeloid leukemia and the evaluation and application of the new cancer marker JAK2.
- Promoted a Center for the Study of Leukemia and Myeloproliferative Neoplasm at Weill Cornell Medical College. Funded the establishment of the Richard T. Silver MD Myeloproliferative Neoplasm Center at Weill Cornell Medical College that was dedicated in early 2014.
- Participated in the development of new chemotherapies for Hodgkin’s disease and non-Hodgkin’s lymphoma.
- Developed the use of interferon alfa as a treatment for polycythemia vera and other myeloproliferative neoplasm.
- Established a working knowledge of why and how breast cancers spread.
- Developed new drugs to treat breast cancer.
- Identified the processes of blood cell formation that initiated a novel treatment for blood diseases and solid tumor cancers through anti-angiogenesis.
- Collaborated with scientists at Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, Wessex Regional Genetics Laboratory, Salisbury, UK and Cornell University.
- Developed new, targeted therapies, producing many new drugs that give hope to cancer patients.
We encourage you to explore our Research Stories to learn more about the impact of the cancer research CR&T has funded and the advances being made by many of today’s leading physician-scientists.